Copyright
©The Author(s) 2021.
World J Clin Oncol. Oct 24, 2021; 12(10): 868-881
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.868
Published online Oct 24, 2021. doi: 10.5306/wjco.v12.i10.868
Trial | Phase | Participants | Treatment | Efficacy/indentifer |
GOG181B[55] | II | HER2-positive EC (n = 33, endometrioid: 13, serous: 11, clear: 3, others: 6) | Trastuzumab | ORR 0%, mPFS 1.84 mo, mOS 7.8 mo |
GOG229D[56] | II | Persistent or recurrent EC (n = 31, endometrioid: 16, serous: 7, clear: 3, others: 5, HER2-positive: n = 2) | Lapatinib | mPFS 1.82 mo, mOS 7.33 mo |
Fader et al[46,57] | II | HER2-positive USC (n = 61) | carboplatin+paclitaxel+trastuzumab vs carboplatin+paclitaxel | mPFS 12.9 mo vs 8.0 mo, mOS 29.6 vs 24.4 mo |
MyPathway[25] | Phase IIa Multiple basket study | Solid tumor(HER2-positive EC, n = 7) | Trastuzumab+pertuzumab | ORR 0%(EC) |
Li et al[59] | II | HER2 amplified cancer (endometrial cancer: n = 18) | Trastuzumab emtansine | Endometrial cancers: CR 2, PR 2 |
DESTINY-PanTumor02[77] | II | HER2 expressing tumor (urothelial, biliary tract, cervical, endometrial, ovarian, pancreatic, rare tumors) | Trastumab deruxtecan | NCT04482309 |
Veneris[78] | I | HER2-positive USC | Trastuzumab deruxtecan+olaparib | NCT04585958 |
Banerji et al[61] | I | Dose-expansion cohort: HER2-positive breast, gastric, urothelial, endometrial cancer | SYD-985 (Trastuzumab duocarmazine) | Endometrial cancer: ORR 39%, mPFS 4.3 mo |
Koper[79] | I | HER2-positive solid tumor | SYD-985 (Trastuzumab duocarmazine)+Niraparib | NCT04235101 |
Hendriks[80] | II | HER2-positive endometrial cancer | SYD-985 (Trastuzumab duocarmazine) | NCT04205630 |
STATICE[52] | II | HER2-positive UCS | Trastuzumab deruxtecan | UMIN00002956 (NCCH1615) |
Makker[81] | II | HER2-positive endometrial cancer, UCS | ZW25 | NCT04513665 |
Ramos[82] | II | HER2-positive solid tumors | Tucatinib and trastuzumab | NCT04579380 |
- Citation: Saito A, Yoshida H, Nishikawa T, Yonemori K. Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World J Clin Oncol 2021; 12(10): 868-881
- URL: https://www.wjgnet.com/2218-4333/full/v12/i10/868.htm
- DOI: https://dx.doi.org/10.5306/wjco.v12.i10.868